TWST:NASDAQTwist Bioscience Corporation Analysis
Data as of 2026-08-15 - not real-time
$118.57
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Twist Bioscience Corporation is priced at $118.57 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it gained 16.0%. RSI sits at 64.3, which reads as approaching overbought, and MACD momentum is bullish. Watch $80.59 as support and $126.40 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 11.2% below today's level. Revenue is growing at 23.2% on a -31.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 85.0%, a beta of 2.63 and a maximum drawdown of 25.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 11.2% below today's level. Revenue is growing at 23.2% on a -31.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 85.0%, a beta of 2.63 and a maximum drawdown of 25.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
Top Market Events
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan...SOUTH SAN FRANCISCO, Calif., August 04, 2026--Twist Bioscience Corporation Nasdaq: TWST "Twist" , a mid-cap growth and...SOUTH SAN FRANCISCO, Calif., August 04, 2026--As required by the rules of the Nasdaq Stock Market, Twist Bioscience...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 56.33
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 56.33
- Analyst targets imply -11.2% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Negative profit margin of -31.7%
- Analyst targets imply -11.2% versus the current price
- Negative return on equity of -29.6%
Key Metrics & Analysis
Financial Health
Revenue Growth23.20%
Profit Margin-31.66%
P/E Ratio-187.2
ROE-29.59%
ROA-13.09%
Debt/Equity24.36
P/B Ratio16.7
Op. Cash Flow$-53072000
Free Cash Flow$-64822500
Industry P/E29.8
Technical Analysis
TrendBullish
RSI64.3
Support$80.59
Resistance$126.40
MA 20$101.59
MA 50$92.67
MA 200$56.33
MACDBullish
VolumeIncreasing
Fear & Greed Index95.98
Valuation
Target Price$105.30
Upside/Downside-11.19%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.63
Volatility84.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.